Drug Sponsors

Novartis launches affordable medicines portfolio

Thursday, September 24, 2015

Novartis has launched Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for $1 per treatment, per month.

[Read More]

Clinigen to acquire Link Healthcare

Wednesday, September 23, 2015

Clinigen Group, a specialty global pharmaceutical company, has agreed to acquire Link Healthcare, a specialist pharmaceutical and medical technology business focused on the Asia, Africa and Australasia (AAA) region, for an initial consideration of $67.9 million and a maximum of approximately $152.5 million based on achievement of milestones.

[Read More]

Bayer splits into thirds

Wednesday, September 23, 2015

Following the economic and legal separation of Covestro, Bayer is charting the course for its successful development as a life science company. From Jan. 1, 2016, the company’s business will be managed by three divisions: Pharmaceuticals, Consumer Health and Crop Science. The present structure of a strategic management holding company and operational subgroups will be replaced by an integrated organization under the umbrella of the strong Bayer brand.

[Read More]

Nanomedical Diagnostics launches

Monday, September 21, 2015

Nanomed co-founders Ross Bundy and Dr. Brett Goldsmith have launched Nanomedical Diagnostics, a San Diego-based biotech company developing and commercializing bioelectronics for use in research and diagnostics. Nanomed’s first product, AGILE Research, a label-free, quantitative, low-cost biosensor for small molecule and protein analysis, is entering beta testing this fall and planned for commercial release in early 2016.

[Read More]